 |
Oliver Sartor, MD, medical director, Tulane Cancer Center, explains that ... Posted by: OncLiveTV
Video duration: 70 seconds Oliver Sartor, MD, medical director, Tulane Cancer Center, explains that there is no question that PSA screening detects many cancers that do not need to be treated. To him, the larger question is whether there is enough knowledge to determine which patients should be treated and which should not. Read more at http://www.onclive.c om/onclive-tv/Dr-Oli ver-Sartor-Discusses -PSA-Screening |
 |
Dr. Nancy Davidson on Screening for Ovarian Cancer Posted by: OncLiveTV
Video duration: 75 seconds Nancy E. Davidson, MD, director, University of Pittsburgh Cancer Institute and UPMC Cancer Centers, discusses two methods of screening for ovarian cancer, which have both been proven to be ineffective. |
 |
Dr. Andre Goy on Neoadjuvant Leuprolide and Abiraterone in High Risk Localized Prostate Cancer Posted by: OncLiveTV
Video duration: 95 seconds Andre Goy, MD, MS, chief, Lymphoma Division, chairman, John Theurer Cancer Center at Hackensack University Medical Center, discusses a phase II trial that combined leuprolide acetate with abiraterone acetate before prostatectomy in patients with localized high-risk prostate cancer. Read more at http://www.onclive.c om/onclive-tv/Dr-Goy -on-Neoadjuvant-Horm onal-Therapy-Plus-Zy tiga |
 |
Dr. Michael Rotkowitz on the Dabrafenib Plus Trametinib Combination for Melanoma Posted by: OncLiveTV
Video duration: 48 seconds Michael Rotkowitz, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses bypassing resistance in patients with melanoma that are receiving vemurafenib. Read more at http://www.onclive.c om/conference-covera ge/asco-2012/Dr-Rotk owitz-on-the-Dabrafe nib-Trametinib-Combi nation |
 |
Dr. Shayma Kazmi on Olanzapine for Breakthrough Chemotherapy-Induced Nausea and Vomiting Posted by: OncLiveTV
Video duration: 63 seconds Shayma Kazmi, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses olanzapine for breakthrough chemotherapy-induced nausea and vomiting. Read more at http://www.onclive.c om/conference-covera ge/asco-2012/Dr-Kazm i-Discusses-Olanzapi ne-for-Breakthrough- CINV |
 |
Dr. Paul Chapman on BRAF and MEK Inhibitor Combination for Advanced Melanoma Posted by: OncLiveTV
Video duration: 93 seconds Paul B. Chapman, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses combination therapy with dabrafenib and trametinib, two investigational agents for patients with advanced melanoma that have a V600 BRAF mutation. View more at http://www.onclive.c om/conference-covera ge/asco-2012/Dr-Chap man-on-BRAF-MEK-Comb ination-for-Melanoma |
 |
Dr. Neil Spector Discusses Breast Cancer Heterogeneity Posted by: OncLiveTV
Video duration: 136 seconds Neil L. Spector, MD, co-director, Experimental Therapeutics, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, explains the need for an ample interpretation of breast cancer heterogeneity. Read more at http://www.onclive.c om/onclive-tv/Dr-Spe ctor-Explains-Breast -Cancer-Heterogeneit y |
 |
Dr. Stephen Ansell on Treating Patients With Waldenström Macroglobulinemia Posted by: OncLiveTV
Video duration: 61 seconds Stephen Ansell, MD, PhD, professor of medicine at the Mayo Clinic in Minnesota, discusses using rituximab (Rituxan) to treat subgroups of patients with Waldenström Macroglobulinemia (WM), a rare type of slow-growing non-Hodgkin lymphoma. Read more at http://www.onclive.c om/onclive-tv/Dr-Ans ell-on-Treating-Wald enstrm-Macroglobulin emia |
 |
Nurses Discuss the Value of the ONS Annual Congress Posted by: OncLiveTV
Video duration: 210 seconds Five nurses discuss the value of the Oncology Nursing Society (ONS) Annual Congress, which is the largest meeting held specifically for oncology nurses. The meeting offers many ancillary events, as well as satellite symposia and cutting-edge sessions. Read more at http://www.onclive.c om/conference-covera ge/ons-2012/Nurses-D iscuss-the-Value-of- the-ONS-Annual-Congr ess |
 |
Dr. Matthew Ellis on Heterogeneity Impacting Biomarker Efficacy Posted by: OncLiveTV
Video duration: 72 seconds Matthew J. Ellis, MD, PhD, professor of medicine, director, Breast Cancer Program, Siteman Cancer Center, discusses the impact that tumor level heterogeneity has on the efficacy of biomarkers for patients with breast cancer. Read more at http://www.onclive.c om/onclive-tv/Dr-Ell is-on-Heterogeneity- Impacting-Biomarker- Efficacy |
 |
Dr. Robert Dreicer on Utilizing New Prostate Cancer Therapies Posted by: OncLiveTV
Video duration: 61 seconds Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute at the Cleveland Clinic, discusses many of the issues that are delaying the utilization of new therapies to treat patients with prostate cancer. Read more at http://www.onclive.c om/onclive-tv/Dr-Dre icer-on-Utilizing-Ne w-Prostate-Cancer-Th erapies |
 |
ONS 37th Annual Congress Slideshow Posted by: OncLiveTV
Video duration: 107 seconds The Oncology Nursing Society 37th Annual Congress, at the New Orleans Ernest N. Morial Convention Center, offers four full days of programming, dozens of exhibitors, satellite symposia, and has thousands of members in attendance. The conference facilitates interactions between oncology nurses from all parts of the US, while ensuring the educational needs of all attendees are met. |
 |
Carol Bush, BS, RN, on the Midwest Cancer Alliance Telehealth Network Posted by: OncLiveTV
Video duration: 77 seconds Carol J. Bush, BS, RN, Patient Navigator, Midwest Cancer Alliance, The University of Kansas Cancer Center, discusses the telehealth network used by the Midwest Cancer Alliance (MCA) to provide access to the ONS Chemotherapy and Biotherapy training for oncology nurses in rural areas. Read more at http://www.onclive.c om/conference-covera ge/ons-2012/Carol-Bu sh-on-the-MCA-Telehe alth-Network |
 |
Krista Rubin, MS, RN, FNP-BC, on Managing Ipilimumab-related Dermatitis Posted by: OncLiveTV
Video duration: 71 seconds Krista Rubin, MS, RN, FNP-BC, Center for Melanoma, Massachusetts General Hospital Cancer Center, discusses the management of immune-mediated dermatitis, a common side effect of ipilimumab (Yervoy), an immunotherapy used to treat patients with advanced melanoma. |
 |
Erin McMenamin, MSN, on HPV-related Head & Neck Cancer Prognosis Posted by: OncLiveTV
Video duration: 63 seconds Erin McMenamin, MSN, Radiation Oncology, Hospital of the University of Pennsylvania, discusses the prognosis for patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the head and neck. |
 |
Anna Vioral, RN, OCN, on Multidisciplinary Chemotherapy Safety Standards Posted by: OncLiveTV
Video duration: 52 seconds Anna Vioral, MSN, MEd, RN, OCN®, Oncology, West Penn Allegheny Health System, summarizes a three year effort to standardize and integrate a set of multidisciplinary chemotherapy safety standards, which used the preexisting recommendations from the American Society of Clinical Oncology (ASCO) and Oncology Nursing Society (ONS). |
 |
Michael Eckenfels, RN, OCN, on Changes to the Bortezomib Delivery Route Posted by: OncLiveTV
Video duration: 41 seconds Michael Eckenfels, BSN, LMSW, RN, OCN®, Lymphoma Myeloma Center, MD Anderson Cancer Center, discusses a nurse-led project that sought to reduce the incidence of bortezomib (Velcade)-related peripheral neuropathy in patients with multiple myeloma. Read more at http://www.onclive.c om/conference-covera ge/ons-2012/Michael- Eckenfels-on-Bortezo mib-Delivery-Route-C hanges |
 |
Mary Gullatte Discusses Nursing Shortages Posted by: OncLiveTV
Video duration: 86 seconds Mary Gullatte, PhD, RN, APRN, BC, AOCN®, FAAN, associate chief nursing officer, Emory University Hospital Midtown, president, Oncology Nursing Society, discusses the factors that contribute to nursing shortages and what may be behind an apparent lack of shortages. Read more at http://www.onclive.c om/conference-covera ge/ons-2012/Mary-Gul latte-Discusses-Nurs ing-Shortages |
